N-(2,6-diethylphenyl)hydrazinecarbothioamide | 122813-70-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(2,6-diethylphenyl)hydrazinecarbothioamide
• 英文别名: 1-amino-3-(2,6-diethylphenyl)thiourea
• CAS: 122813-70-1
• 化学式: C₁₁H₁₇N₃S
• 分子量: 223.342
• InChiKey: WEOWLTWQARWBQZ-UHFFFAOYSA-N

物化性质

• 沸点：
  337.9±52.0 °C(Predicted)
• 密度：
  1.163±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  82.2
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-硝基糠醛 、 N-(2,6-diethylphenyl)hydrazinecarbothioamide 在 溶剂黄146 作用下， 以53.8%的产率得到1-(2,6-diethylphenyl)-3-[(5-nitrofuran-2-yl)methylideneamino]thiourea
  参考文献：
  名称：

  5-Nitrofuran-2-yl derivatives: Synthesis and inhibitory activities against growing and dormant mycobacterium species

  摘要：

  Eighteen 5-nitrofuran-2-yl derivatives were prepared by reacting 5-nitro-2-furfural with various (sub)phenyl/pyridyl thiosemicarbazide using microwave irradiation. The compounds were tested for their in vitro activity against tubercular and various non-tubercular mycobacterium species in log-phase and 6-week-starved cultures. Compound N-(3,5-dibromopyridin-2-yl)-2-((5-nitrofuran-2-yl) methylene) hydrazinecarbothioamide (4r) was found to be the most potent compound (MIC: 0.22 mu M) and was 3 times more active than standard isoniazid (INH) and equally active as rifampicin (RIF) in log-phase culture of Mycobacterium tuberculosis H37Rv. In starved M. tuberculosis H37Rv, 4r inhibited with MIC of 13.9 mu M and was found to be 50 times more active than INH and slightly more active than RIF. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.12.088
• 作为产物：
  描述：

  potassium (2,6-diethylphenyl)carbamodithioate 在 一水合肼 作用下， 以 乙醇 为溶剂， 反应 1.0h， 生成 N-(2,6-diethylphenyl)hydrazinecarbothioamide
  参考文献：
  名称：

  5-Nitrofuran-2-yl derivatives: Synthesis and inhibitory activities against growing and dormant mycobacterium species

  摘要：

  Eighteen 5-nitrofuran-2-yl derivatives were prepared by reacting 5-nitro-2-furfural with various (sub)phenyl/pyridyl thiosemicarbazide using microwave irradiation. The compounds were tested for their in vitro activity against tubercular and various non-tubercular mycobacterium species in log-phase and 6-week-starved cultures. Compound N-(3,5-dibromopyridin-2-yl)-2-((5-nitrofuran-2-yl) methylene) hydrazinecarbothioamide (4r) was found to be the most potent compound (MIC: 0.22 mu M) and was 3 times more active than standard isoniazid (INH) and equally active as rifampicin (RIF) in log-phase culture of Mycobacterium tuberculosis H37Rv. In starved M. tuberculosis H37Rv, 4r inhibited with MIC of 13.9 mu M and was found to be 50 times more active than INH and slightly more active than RIF. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.12.088

文献信息

• 3-amino-5-methyl-1H-pyrazole-4-carboxylic acids and esters thereof as
  申请人：A. H. Robins Company, Incorporated

  公开号：US04826866A1

  公开（公告）日：1989-05-02

  A novel method of controlling epilepsy, muscle tension, muscular spasticity, and anxiety in living animal bodies by administering compounds of the formula: ##STR1## wherein: R.sup.1 is hydrogen, loweralkyl or a pharmaceutically acceptable cation; R.sup.2 and R.sup.3, same or different, are hydrogen, loweralkyl, aryl, cycloalkyl, loweralkenyl, 1-adamantyl, heterocyclicaminoalkyl, diloweralkylaminoloweralkyl, or R.sup.2 with R.sup.3 and adjacent nitrogen may form a heterocyclic ring structure; and the pharmaceutical acceptable acid salts, and tautomeric isomers thereof; and novel pharmaceutical compositions therefor are disclosed.

  本发明涉及一种控制癫痫、肌肉紧张、肌肉痉挛和焦虑的新方法，其通过给予以下公式的化合物进行实现：##STR1##其中：R.sup.1是氢、低碳基或药学上可接受的阳离子；R.sup.2和R.sup.3，相同或不同，是氢、低碳基、芳基、环状碳基、低烯基、1-金刚烷基、杂环氨基烷基、二低碳基氨基低碳基，或R.sup.2与R.sup.3和相邻的氮原子可以形成杂环环结构；以及其药学上可接受的酸盐和互变异构体；并且还公开了新的药物组合物。
• 3-Amino-5-methyl-1H-pyrazole-4-carboxylic acids and esters thereof as
  申请人：A. H. Robins Company, Incorporated

  公开号：US04871737A1

  公开（公告）日：1989-10-03

  A novel method of controlling epilepsy, muscle tension, muscular spasticity, and anxiety in living animal bodies by administering compounds of the formula: ##STR1## wherein: R.sup.1 is hydrogen, loweralkyl or a pharmaceutically acceptable cation; R.sup.2 and R.sup.3, same or different, are hydrogen, loweralkyl, aryl, cycloalkyl, loweralkenyl, 1-adamantyl, heterocyclicaminoalkyl, diloweralkylaminoloweralkyl, or R.sup.2 with R.sup.3 and adjacent nitrogen may form a heterocyclic ring structure; and the pharmaceutical acceptable acid salts, and tautomeric isomers thereof; and novel pharmaceutical compositions therefor are disclosed.

  本发明涉及一种通过给活体动物体内注射化合物的方法来控制癫痫、肌肉紧张、肌肉痉挛和焦虑，所述化合物的结构式为：##STR1## 其中：R1为氢、低碳基或药学上可接受的阳离子；R2和R3相同或不同，为氢、低碳基、芳基、环烷基、低碳烯基、1-金刚烷基、杂环氨基烷基、二低碳基氨基低碳基，或R2与R3及相邻的氮原子可形成杂环环状结构；以及其药学上可接受的酸盐和互变异构体；以及新型的药物组合物。
• 3-amino-5-methyl-1H-pyrazole-4-carboxylic acids and esters thereof as anticonvulsants, muscle relaxants and anxiolytics
  申请人：A.H. ROBINS COMPANY, INCORPORATED

  公开号：EP0315433A2

  公开（公告）日：1989-05-10

  Pharmaceutical compositions which comprise a compound represented by the formula where R¹ represents a hydrogen atom, a lower alkyl group or a pharmaceutically acceptable cation; R² and R³ independently represent a hydrogen atom, a lower alkyl group, an aryl group, a cycloalkyl group, a lower alkenyl group, a 1-adamantyl group, a hetero­cyclicaminoalkyl group, a diloweralkylaminoloweralkyl group, or R² together with R³ and the adjacent nitrogen atom may form a heterocyclic ring structure; and/or a pharmaceutically acceptable acid salt thereof; the use of such compounds in medicine; and the use of such compounds in the preparation of anticonvul­sant agents, muscle relaxants and anxiolytic agents, are disclosed.

  药物组合物，其中包含由式表示的化合物 其中 R¹ 代表氢原子、低级烷基或药学上可接受的阳离子； R²和R³各自代表氢原子、低级烷基、芳基、环烷基、低级烯基、1-金刚烷基、杂环氨基烷基、稀释烷基氨基低级烷基，或R²与R³及相邻氮原子可形成杂环环结构； 和/或其药学上可接受的酸盐；公开了此类化合物在医药中的用途；以及此类化合物在制备抗惊厥剂、肌肉松弛剂和抗焦虑剂中的用途。
• COMPOSITIONS AND USES FOR ENHANCING VIRUS PRODUCTION
  申请人：Ottawa Hospital Research Institute

  公开号：EP2451795B1

  公开（公告）日：2016-07-13
• COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY
  申请人：Bell John

  公开号：US20120134963A1

  公开（公告）日：2012-05-31

  Provided are viral sensitizing compounds that enhance the efficacy of viruses by increasing spread of the virus in cells, increasing the titer of virus in cells, or increasing the cytotoxicity of virus to cells. Other uses, compositions and methods of using same are also provided.